Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Phase 2
50
about 5.1 years
40–80
3 sites in AL, MI, PA
About this study
This trial is testing whether ensifentrine, a medication, helps reduce inflammation markers in the sputum of people with COPD. Participants will receive either ensifentrine or a placebo for two periods of 8 weeks each. It lasts up to 24 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ensifentrine
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Respiratory System Agent (Phosphodiesterase 3 Inhibitors)
Primary: The change from baseline in sputum neutrophils at Week 8 (absolute change in cell numbers)
Secondary: The change from baseline in FEV1 after 4 weeks, The change from baseline in FEV1 after 8 weeks (post-dose), The change from baseline in FRC after 4 weeks, The change from baseline in FRC after 8 weeks (post-dose)., The change from baseline in FVC after 4 weeks, The change from baseline in FVC after 8 weeks (post-dose), The change from baseline in RV after 4 weeks, The change from baseline in RV after 8 weeks (post-dose)
Respiratory